p53CM1 expression is not associated with prognosis in uterine cervical carcinoma.
METHODS
Specimens obtained from 192 patients with Stage III squamous cell carcinoma of the cervix treated by radiation therapy alone were investigated with an immunohistochemical method for the expression of p53CM1, a monoclonal antibody that recognizes wild and mutant type p53 gene products in histologic materials fixed and processed conventionally.


RESULTS
Cancer cells that had positive results for p53CM1 showed a nuclear staining pattern. Of the 192 patients, 99 had tumors that had negative findings (-) for p53CM1, 44 had tumors that were weakly reactive or ambiguous (+/-), 36 had tumors with positive results (+), and 13 had strongly reactive tumors (++). There was no significant correlation between survival of patients and p53CM1 (-) or (+/-) expression or p53CM1 (+) or (++) expression (chi-square test and Kaplan-Meier method, P = 0.466).


CONCLUSIONS
The p53CM1 expression in cancer cells is not a predictive factor for the prognosis of patients with cervical carcinoma.
Section of Clinical Laboratory, National Institute of Radiological Sciences, Chiba, Japan.
K
K
Oka
T
T
Nakano
T
T
Arai
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000532:radiotherapy
D000911:Antibodies, Monoclonal; D016159:Tumor Suppressor Protein p53